ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.

AstraZeneca

Status and phase

Completed

Phase 3

Conditions

Breast Cancer

Treatments

Drug: Anastrozole

Drug: Tamoxifen

Study type

Interventional

Funder types

Industry

Identifiers

NCT00291759

ABCSG 8

1033AU/0002

Details and patient eligibility

About

The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.

Enrollment

3,858 patients

Sex

Female

Ages

Under 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Invasive mammary carcinoma after radical treatment, without prior chemo/hormone/radiation therapy.
At least 6 lymph nodes examined.
Good or intermediate tumour differentiation.
<6 weeks before start of adjuvant therapy.
Oestrogen or Progesterone positive

Exclusion criteria

Premenopausal.
Preoperative hormonal/antihormonal/radiation/cytoxic chemo. Second malignant tumour/status post second malignant tumour.
In-situ/T4 carcinoma.
Age >80 years.
World Health Organisation performance index >3.
Serious accompanying diseases